Form 4: Eli Lilly Executive Jacob Van Naarden Reports Stock Transactions
SEC Form 4 Filing
EVP & President of Lilly Oncology, Jacob Van Naarden, reports the acquisition and disposal of Eli Lilly & Co. common stock and restricted stock units on February 1, 2025.
Summary
- On February 1, 2025, Jacob Van Naarden, EVP & President of Lilly Oncology, reported transactions involving Eli Lilly & Co. stock.
- These transactions included the acquisition of 3,023 shares of common stock through the exercise of restricted stock units.
- Van Naarden also disposed of 1,409.839 shares of common stock to cover tax obligations at a price of $811.08 per share.
- Following these transactions, Van Naarden directly owns 13,458.161 shares of common stock.
- He also indirectly owns 4,342 shares through the Van Naarden Family Trust and 4,302 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
This is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- Shareholders are informed about insider trading activities, promoting transparency.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | Date of stock transactions (acquisition and disposal). |
| 02/04/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.